COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Future Cardiology, published by Future Medicine Ltd, is an esteemed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With an ISSN of 1479-6678 and an E-ISSN of 1744-8298, this journal has been serving as a vital platform for researchers and healthcare professionals since its inception in 2006. The journal features rigorously peer-reviewed articles, offering insights into innovative treatments, clinical studies, and cutting-edge research developments. Although it is currently categorized as Q3 in Cardiology and Cardiovascular Medicine and Q4 in Molecular Medicine, its growing impact is evident in its dedicated audience and commitment to fostering dialogue in the cardiovascular community. Future Cardiology provides an invaluable opportunity for scholars to share their findings and enhance knowledge in this critical area of healthcare, a pursuit that is ever more important as cardiovascular diseases continue to be a leading health concern worldwide. Access options are through standard subscriptions, allowing in-depth exploration of articles that push the boundaries of cardiological science.

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

Nepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.

The American Journal of Cardiology is a leading peer-reviewed journal in the field of Cardiology and Cardiovascular Medicine, published by Excerpta Medica Inc-Elsevier Science Inc. Since its inception in 1958, the journal has consistently contributed to the advancement of cardiovascular research, providing a platform for groundbreaking studies and clinical findings that shape modern medical practices. With an impressive impact factor placing it in the Q1 category in its field for 2023, it ranks among the top journals in medicine, with a rank of #155 out of 387 in the Scopus database, reflecting its significance and rigorous editorial standards. The journal is committed to disseminating high-quality research that fosters innovation and enhances clinical outcomes in cardiology. Although it does not provide Open Access options, the American Journal of Cardiology remains an essential resource for researchers, healthcare professionals, and students looking to deepen their understanding of cardiovascular health.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.